Impact Biomedical Inc(US:IBO)2026-03-11 21:31Intellectual Property and Technology - Impact BioMedical has expanded its intellectual property portfolio to include sixty (60) issued and over sixty (60) pending patents by the end of 2025[42]. - The company announced the acquisition of Celios Air Purification technology, which captures up to 99.99% of ultrafine particles down to 10 nanometers, significantly exceeding traditional HEPA standards[43]. - Impact BioMedical entered a definitive merger agreement with Dr. Ashleys Limited, combining global pharmaceutical manufacturing with its patent portfolio to accelerate revenue generation[44]. - The Equivir platform, licensed to ProPhase Labs, is planning for potential commercialization, contingent on meeting targeted marketing claims[42]. - Laetose technology has shown potential to reduce sugar consumption by 30% and lower caloric and glycemic index/load[29]. - The 3F technology received a U.S. allowance for infectious disease applications, designed to act as an antibacterial or antiviral agent[49]. - Linebacker compounds have been licensed to ProPhase Laboratories for development and commercialization, with potential future milestone and royalty payments[26]. - The company is actively seeking partners for further development and commercialization of Laetose and 3F technologies worldwide[30][32]. - The company’s intellectual property rights may not provide a significant competitive advantage, and enforcement of these rights could be challenging, particularly in less developed jurisdictions[91]. - The company may face increased litigation related to intellectual property rights as it grows, which could be costly and divert management's attention from core business activities[93]. Financial Performance and Position - The company has incurred significant operating losses since its inception and expects to continue incurring losses for the foreseeable future, with no revenue generated to date[81]. - For the year ended December 31, 2025, the company recorded a net loss of $11,870,000, a 52% decrease from the net loss of $24,770,000 for the year ended December 31, 2024[172]. - Total revenue for the year ended December 31, 2025 was $32,000 from biotech retail sales, with no revenue reported for the previous year[157]. - The company reported total costs and expenses of $4,314,000 for the year ended December 31, 2025, a significant decrease of 85% from $28,753,000 in 2024[158]. - Operating loss for 2025 was $4,282,000, a decrease from the operating loss of $28,753,000 in 2024, reflecting improved operational efficiency[208]. - Net loss attributable to common stockholders for 2025 was $11,838,000, compared to a net loss of $24,708,000 in 2024, showing a reduction in losses[208]. - Cash and cash equivalents at the end of 2025 were $3,000, down from $1,999,000 at the end of 2024, indicating liquidity challenges[211]. - Total assets decreased to $17,405,000 in 2025 from $20,290,000 in 2024, reflecting a decline in overall company value[205]. - Total liabilities decreased significantly from $13,053,000 in 2024 to $1,850,000 in 2025, indicating improved financial health[205]. Operational Challenges and Risks - The company is focused on the advancement of drug discovery and prevention for neurological, oncological, and immune-related diseases, as well as developing initiatives to curb airborne infectious diseases[65]. - The company relies on collaborative agreements with third parties for product development, exposing it to risks if these partnerships fail[80]. - The company faces significant competition from larger pharmaceutical and biotechnology companies, which may have greater resources and experience[76]. - The company is dependent on third-party manufacturers for clinical drug supplies, which may impair the development of its drug candidates[87]. - The company must successfully develop, register, and commercialize multiple technologies to achieve profitability, which remains uncertain[82]. - The company is subject to risks related to corporate social responsibility and reputational matters, which could negatively impact its business[73]. - The company may require additional financing to meet its current and projected cash requirements for operations[74]. - The company relies on third-party manufacturers for regulatory compliance and quality assurance, which poses risks of potential breaches and nonrenewal of manufacturing agreements[90]. - The company’s ability to implement applications and services depends on third-party technology and intellectual property, and any failure from these vendors could adversely affect financial results[96]. Corporate Governance and Structure - The company currently has two full-time employees and six shared employees as of December 31, 2025[66]. - The company is classified as an "emerging growth company," which allows it to take advantage of reduced disclosure requirements, potentially affecting its attractiveness to investors[106]. - The company may remain an "emerging growth company" until certain financial thresholds are met, including revenues exceeding $1.235 billion[108]. - The company’s financial accounting may be perceived as less transparent compared to other industry players, impacting investors' ability to compare its business effectively[109]. - The company is currently listed on the NYSE American LLC Exchange, and compliance with listing standards is crucial to avoid delisting[110]. - As of March 6, 2026, there are 556 record holders of the company's common stock, excluding shares held in nominee or street name accounts[129]. - The company did not pay dividends in 2024 or 2025, and plans to retain earnings for business investment[130]. Research and Development - Research and development costs rose by 22% to $340,000 for the year ended December 31, 2025, driven by expenses related to existing and developing patents[163]. - The company has several proprietary technologies in development, including Linebacker, Laetose, and Functional Fragrance Formulation (3F)[141]. - The company is actively seeking partners for the commercialization of Laetose and 3F technologies[148][150]. Legal and Compliance - No material legal proceedings are currently affecting the company or its subsidiaries[123]. - The cybersecurity program is overseen by the VP of Engineering & Technology, ensuring robust risk management and compliance[119]. - There have been no material changes to critical accounting policies as of the Annual Report on Form 10-K for the year ended December 31, 2025[182]. - The company has no off-balance sheet arrangements that are likely to affect its financial condition, revenues, or expenses[180]. - Inflation did not have a material effect on the Company's results of operations during 2024 or 2025[181]. Capital and Financing - The company is exploring options to raise capital, including a listing on the NYSE American under the ticker symbol IBO and debt financing, while also planning to monetize its intellectual properties and control operating costs[179]. - The company issued 1,500,000 shares in 2024, raising $3,726,000, which contributed to its capital structure[213]. - The acquisition of DSS PureAir assets was completed for $820,000, indicating strategic expansion efforts[213].